• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

    2/1/24 5:30:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email

    - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET -

    REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET. The webcast will include Szilard Kiss, M.D., Professor of Ophthalmology at Weill Cornell Medical College and an investigator in Adverum's LUNA Phase 2 study. Adverum will further detail these preliminary results at the 47th Annual Meeting of the Macula Society. The preliminary LUNA results will include safety and efficacy data at both the 2E11 and 6E10 dose levels. LUNA was fully enrolled in August 2023.

    Macula Society Meeting Presentation Information
      Title: Ixoberogene soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: Preliminary Results from the Phase 2 LUNA Study
      Date / Time: Thursday, February 8th, 2024 at 10:56am ET, 7:56 am PT
      Session: AMD II Neovascular Trials
      Presenter: Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates, Clinical Associate Professor at University of Nevada, Reno School of Medicine
      

    The presentation from Macula Society will be available on the News and Publications section of Adverum's website shortly after the presentation.

    Conference Call and Webcast Information

    Adverum will host a conference call and webcast on Thursday, February 8th, 2024 at 8:00 am ET to discuss the preliminary safety and efficacy data from the LUNA Phase 2 study of Ixo-vec. To access the webcast presentation, please click here.

    The on-demand webcast presentation may be accessed under Events and Presentations in the Investors section of Adverum's website. A replay of the webcast will be available on the website following the presentation.

    About Adverum Biotechnologies

    Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

    Forward-looking Statements

    Statements contained in this press release regarding events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the anticipated release of initial preliminary efficacy and safety data from the LUNA trial. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation: Adverum's novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials; regulatory uncertainties; enrollment uncertainties; the results of early clinical trials not always being predictive of future clinical trials and results; and the potential for future complications or side effects in connection with use of Ixo-vec. Additional risks and uncertainties facing Adverum are set forth under the caption "Risk Factors" and elsewhere in Adverum's Securities and Exchange Commission (SEC) filings and reports, including Adverum's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 9, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Inquiries:

    Adverum Investor Relations

    Email: [email protected]



    Primary Logo

    Get the next $ADVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Financials

    Live finance-specific insights

    See more
    • Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

      REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

      7/10/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

      - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

      2/1/24 5:30:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

      REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

      12/7/23 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Adverum Biotechnologies Inc.

      SCHEDULE 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      5/6/25 9:15:54 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

      DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:02:59 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Adverum Biotechnologies Inc.

      DEF 14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      4/28/25 4:01:46 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADVM
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

      - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

      11/4/24 4:39:45 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

      REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

      10/16/24 8:00:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

      - 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reporte

      8/12/24 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:57:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 6:40:56 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

      SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

      11/14/24 4:05:12 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common

      5/2/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

      REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2024. The company also provided pipeline highlights and updates to anticipated milestones. "We believe Ixo-vec is poised to redefine the standard of care for patients with wet AMD as a potential best-in-class, one-and-done gene therapy. Ixo-vec offers the potential for life-long vision preservation and a favorable safety profile and is overwhelmingly preferred by patients over tod

      4/15/25 7:40:00 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 30,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $3.83 per share, Adverum's closing trading price on the grant date, and will vest over four years,

      4/4/25 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Adverum Biotech with a new price target

      Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

      6/25/24 8:10:21 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

      H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

      4/30/24 6:15:49 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotech upgraded by Truist with a new price target

      Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00

      7/7/22 7:11:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care